Company Overview

CytoDyn is a publicly traded biotechnology company focused on the development of new therapies for combating infection with immune deficiency viruses. CytoDyn's lead product candidate, leronlimab (PRO 140), has the potential to drive groundbreaking advancements in developing the next generation of HIV treatments.

CytoDyn CEO Highlights leronlimab (PRO 140) for Investors

Interview focused on company milestones, a pending acquisition and an array of new indications beyond the expected FDA approval for HIV treatment

View Video
CytoDyn CEO Highlights leronlimab (PRO 140) for Investors
View Detailed Stock Data

Stock Info

CYDY Symbol
OTCQB Market
Market Cap

Upcoming Events

CDRH Face-to-Face Meeting

August 28, 2019

Recent Events

2019 American Society for Microbiology (ASM) Microbe Conference

June 20 - June 24, 2019

Title: Final Results of Pivotal Study of Leronlimab (PRO 140) SC
in Heavily Treatment-Experienced HIV Patients
Presenter: Dr. Kush Dhody & Nader Pourhassan, Ph.D.
Session Title: Novel Biological Therapeutics
Session Date/Time: June 21, 2019 1:30 pm – 4:00 pm
Presentation Time: June 21, 2019 2:00 pm
Moscone Center: 201/202 South

View Press Releases

Recent News